TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01523054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol- Toprol XL
Description: Extended release tablet, 200mg once daily for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol- Lopressor
Description: Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
Study: NCT00224874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin Diftitox
Description: Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
Study: NCT00845663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
Study: NCT03674008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
Study: NCT01494688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5509554
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5509554
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5509554
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5509554
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
Study: NCT03724110

Intervention type: OTHER
Intervention: Telestroke
Description: Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
Study: NCT02442479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Study: NCT03414866

Intervention type: BEHAVIORAL
Intervention: EQ-5D-5L QOL questionnaire
Description: Written questionnaire

Intervention type: BEHAVIORAL
Intervention: EQ-5D-5L QOL questionnaire
Description: Written questionnaire

Intervention type: BEHAVIORAL
Intervention: EQ-5D-5L QOL questionnaire
Description: Written questionnaire
Study: NCT01748890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonoelastography
Description: Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
Study: NCT01680679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Trivalent Influenza Vaccine (TIV)
Study: NCT04377425

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 swap test PCR
Description: COVID-19 swap test PCR performed according to hospital standard operating procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 swap test PCR
Description: COVID-19 swap test PCR performed according to hospital standard operating procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 swap test PCR
Description: COVID-19 swap test PCR performed according to hospital standard operating procedures
Study: NCT03627026

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples will be collected at different time points:
Description: * Baseline~* Week 6 Day 1~* Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center.
Study: NCT01680679

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV), trivalent
Study: NCT00783757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Imaging
Description: TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
Study: NCT00820833

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard infant formula
Description: standard infant formula given from 3 to 12 months of age, as per standard requirement
Study: NCT01368276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Description: 125 µg/m² subcutaneous injection
Study: NCT03849365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD VTP
Description: TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
Study: NCT05869097

Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days

Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Study: NCT00820833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula
Description: Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
Study: NCT00956345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
Study: NCT00645164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ointment Vehicle
Description: Subject acts as own control. 20 mg under Finn chambers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenaderm
Description: 20 mg under Finn chambers
Study: NCT01961336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
Study: NCT03067038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with single port device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Three port laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with three port
Study: NCT03960905

Intervention type: OTHER
Intervention: Children with the usage of anti-infective drugs
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Study: NCT01372657

Intervention type: OTHER
Intervention: biometry calculation
Study: NCT03227679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Metabolite Ratio
Description: This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy
Study: NCT05869097

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
Study: NCT01006668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of sevoflurane
Description: Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
Study: NCT03227679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy
Study: NCT04584164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sialendoscopy
Description: The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
Study: NCT02341001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily text message of support
Study: NCT03258567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
Study: NCT00232739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-eluting Coronary Stent
Description: 2.25 Cypher Sirolimus-eluting Coronary Stent
Study: NCT02735681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: meibomian gland probing
Description: Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Left eye Meibomian Gland Probing Control Group
Description: There will be no probing in the left eye. This will be used as a control for the right eye.
Study: NCT04468308

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
Study: NCT01186029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Emend 40mg by mouth 30 minutes before procedure x 1
Study: NCT04266301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sabatolimab
Description: A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
Study: NCT03673306

Intervention type: OTHER
Intervention: Clinical outcomes
Description: Clinical outcomes

Intervention type: OTHER
Intervention: Clinical outcomes
Description: Clinical outcomes
Study: NCT01006668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of propofol
Description: Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
Study: NCT01091662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1600 mg
Description: 1600 mg once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Description: 1200 once per day
Study: NCT04279470

Intervention type: DRUG
Intervention: CAR T-cell and Cellular Therapies
Description: Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
Study: NCT03423758

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample
Study: NCT03376958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
Study: NCT01532245

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two lung ventilation (TLV)
Description: During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one lung ventilation (OLV) without PEEP
Description: During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)
Description: During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
Study: NCT01835145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study: NCT03423758

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample
Study: NCT01835145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02006485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab + TGR-1202
Description: Ublituximab IV infusion TGR-1202 oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab + TGR-1202 + ibrutinib
Description: Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab + TGR-1202 + bendamustine
Description: Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
Study: NCT03846271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.
Study: NCT04235036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
Study: NCT03846271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: an identical amount of placebo nasal spray will be applied to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: an identical amount of placebo nasal spray will be applied to each subject.
Study: NCT00994981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
Study: NCT01146509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept (donepezil hydrochloride)
Description: Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
Study: NCT00162370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere Injectable Suspension
Description: Activated DEFINITY 10ug/kg by bolus injection
Study: NCT00606775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: 2.5-5mg/day
Study: NCT01398280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical aminocaproic acid (ACA) mixed with Vanicream
Description: 25% Aminocaproic acid cream twice daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream moisturizer twice daily for up to 12 weeks
Study: NCT03602651

Intervention type: OTHER
Intervention: Hamilton-anxiety scale (HAM-A)
Description: Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
Study: NCT03872752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FL lay leader training and workshop implementation
Description: Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
Study: NCT01750073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo mastectomy or breast conserving surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT02848248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD123A
Description: Intravenous infusion in 3-week cycles
Study: NCT02108379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinix Nasal Filters
Study: NCT02803268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 middle dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02462707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
Study: NCT02131779

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Men's Workshops
Description: Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Educational Workshops
Description: One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.